

**ASX RELEASE**

**18 March 2021**

## **AMPLIA AND GARVAN INSTITUTE TO ENTER COLLABORATION AGREEMENT**

**Melbourne, Australia:** Amplia Therapeutics Ltd (ASX: ATX), (“Amplia” or the “Company”), a company developing new approaches for the treatment for cancer and fibrosis, is pleased to announce it has signed a Term Sheet for a Collaboration Agreement with the Garvan Institute of Medical Research (“Garvan”) in Sydney Australia. The Term Sheet defines the structure of a collaborative research and clinical development program focused on the use of Amplia’s FAK inhibitor, AMP945 to treat patients with pancreatic cancer.

The collaboration will combine Garvan’s research strength in FAK biology and its extensive clinical research network with Amplia’s proprietary FAK inhibitors and drug development capability. The collaboration will initially target new treatment regimens and optimal patient selection strategies for Amplia’s planned clinical trials of AMP945 in pancreatic cancer patients later this year. Amplia was awarded an Orphan Drug Designation from the US FDA for this indication in March 2019. The Terms also provide for expansion of the collaboration into other therapeutic areas.

Amplia’s CEO and Managing Director, Dr John Lambert, commented that “The purpose of this collaboration is to optimise our planned clinical program for AMP945. Clearly, Garvan’s team has an unsurpassed understanding of FAK biology and access to an extensive clinical network. By leveraging Garvan’s deep understanding of the different biological roles that FAK can play, we aim to optimise the design of our planned clinical trials, recruit the right pancreatic cancer patients and treat them in the right way, giving AMP945 the best chance for success.”

Professor Paul Timpson, Cancer Research Theme Leader at Garvan, a world-renowned expert in FAK biology, has been collaborating with Amplia for over a year and will be the lead scientist in the collaborative research program. Professor Timpson’s group has developed a number of unique models, assays and tools that provide insights into the biology of both pancreatic cancer cells, and the fibrotic tumour microenvironment (TME). It is the fibrotic TME that supports the growth of pancreatic tumours and makes them particularly challenging to treat. The collaborative research program will evaluate the impact AMP945 can have on these biological processes and use those insights to design clinical trials for AMP945 in patients with pancreatic cancer. As well as Prof. Timpson’s laboratory, the collaboration will provide Amplia with access to other scientists and clinicians with expertise in pancreatic cancer.

Garvan’s Professor Paul Timpson noted that “Our ultimate goal is to translate our cancer research and FAK biology into better outcomes for patients. We are delighted to work with Amplia so that AMP945 is tested in cancer patients who most need it and also stand to benefit. We are looking forward to collaborating both before and during Amplia’s planned clinical trials.”

The final Collaboration Agreement is expected to be signed within 90 days. While the terms of the agreement are confidential, they do include future, success-based payments by Amplia to Garvan on AMP945 achieving specified clinical, regulatory and commercial sales milestones.

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

- End -

**For Further Information**

Dr. John Lambert  
CEO and Managing Director  
[john@ampliatx.com](mailto:john@ampliatx.com)  
[www.ampliatx.com](http://www.ampliatx.com)

**About Amplia Therapeutics Limited**

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

**About Garvan Institute of Medical Research**

The Garvan Institute of Medical Research is a leading multi-disciplinary biomedical research institute in Sydney. With 600 of the world's brightest scientific minds working under one roof, collaborating across different areas of research and using the best technologies to investigate diseases, Garvan have revealed causes and treatments for diseases including diabetes, osteoporosis, cancer, immune deficiency and autoimmunity.

[www.garvan.org.au](http://www.garvan.org.au)